Table 1.
Neutralization profiles of SHIVC109F.PB4 and rhesus-adapted viruses SHIVC109P3, SHIVC109P3N, and SHIVC109P4
| Antibody | Neutralizing activitya against: |
|||
|---|---|---|---|---|
| SHIVC109F.PB4 | SHIVC109P3 | SHIVC109P3N | SHIVC109P4 | |
| sCD4 | 0.03 | 0.10 | 0.29 | 1.59 |
| VRC01 | 2.75 | 0.10 | 0.24 | 1.40 |
| PG9 | 0.65 | 0.50 | 0.37 | 0.425 |
| b12 | >50 | >50 | >50 | >50 |
| 2G12 | >50 | >50 | >50 | >50 |
| 2F5 | >50 | >50 | >50 | >50 |
| Polyclonal anti-HIV Ig | ||||
| Clade B | 666.80 | 153.06 | 44.38 | >2,500 |
| Clade C | 123.24 | 30.13 | 10.95 | 360.36 |
| Anti-clade C Igb | ||||
| SA-C2 | 316.15 | 13.46 | 4.31 | 1,329.72 |
| SA-C8 | 178.18 | 32.52 | 7.54 | 258.21 |
| SA-C44 | 167.51 | 6.46 | 2.33 | 258.21 |
| SA-C62 | 406.05 | 56.55 | 16.73 | 1,893.62 |
| SA-C72 | 219.15 | 30.82 | 7.48 | 826.72 |
| SA-C74 | 386.46 | 33.22 | 13.38 | 994.18 |
| Anti-clade B sera | ||||
| HIV-011 | 32 | 109 | 401 | 23 |
| HIV-014 | 127 | 225 | 372 | 117 |
a
Expressed as the IC50 (in micrograms per milliliter) for all antibodies except the anti-clade B sera HIV-011 and HIV-014, for which neutralizing activity is expressed as the ID50 titer (reciprocal of the dilution).
b
From chronically infected patients from South Africa.